



# Early Detection is Not Just for Cervical Cancer

Cervical Cancer: **11,070** new cases per year<sup>1</sup>

Bladder Cancer: **17,580** new cases per year<sup>1</sup>

## The ObGyn is the NEW frontline in the fight against Bladder Cancer.

Testing women with initial symptoms can increase their 5 year survival rate. An NMP22 Test is the only tumor marker approved by the FDA as an aid in the initial diagnosis of bladder cancer<sup>2</sup>; and is now available in an easy to use format.



**Matritech**



**NMP22** BladderChek® Test

An aid in the diagnosis of bladder cancer.

- CLIA Waived
- Easy to use, point of care lateral flow format
- Results in 30 minutes using 4 drops of urine
- On-board Quality Control
- Reimbursement Available\*: CPT-86294QW \$28.64 (2009 CMS National Limit)
- Applicable ICD-9 Codes\*

599.7 Hematuria  
 599.70 Unspecified Hematuria  
 599.71 Gross Hematuria  
 599.72 Microscopic Hematuria

788.1 Dysuria  
 788.41 Urinary frequency  
 788.63 Urgency of urination

When diagnosed early, the 5 year survival rate for bladder cancer is 92%<sup>1</sup>.

### The NMP22® BladderChek® Test

ADD MORE PRECISION TO YOUR PROTOCOL™

Detect bladder cancer before it reaches advanced stages.

Call **1-866-563-5519** or visit **www.Matritech.com** to learn how.

References:

1. American Cancer Society. Cancer Facts & Figures 2008
2. Grossman, et al. Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay, JAMA, February 16, 2005.

\*Dependent on state CMS and Commercial insurance carrier reimbursement guidelines. Confirm RVU's for this CPT code as well as all of the applicable ICD-9 codes with your local providers.

Manufactured by Binax, Inc. for Inverness Medical Innovations North America, Inc., 10 Southgate Road, Scarborough, Maine 04074 USA. Matritech, NMP22, BladderChek and Add More Precision to Your Protocol are trademarks of the Inverness Medical group of companies. ©2009 Inverness Medical. All rights reserved. 09-MATR-0019 RevB

